Bioactive oxylipins in type 2 diabetes mellitus patients with and without hypertriglyceridemia
ObjectiveDyslipidemia, in particular elevated triglycerides (TGs) contribute to increased cardiovascular risk in type 2 diabetes mellitus (T2DM). In this pilot study we aimed to assess how increased TGs affect hepatic fat as well as polyunsaturated fatty acid (PUFA) metabolism and oxylipin formation...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-08-01
|
| Series: | Frontiers in Endocrinology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fendo.2023.1195247/full |
| _version_ | 1797741373004185600 |
|---|---|
| author | Yanan Xiao Yanan Xiao Anne Pietzner Anne Pietzner Nadine Rohwer Nadine Rohwer Nadine Rohwer Adelheid Jung Michael Rothe Karsten H. Weylandt Karsten H. Weylandt Ulf Elbelt Ulf Elbelt |
| author_facet | Yanan Xiao Yanan Xiao Anne Pietzner Anne Pietzner Nadine Rohwer Nadine Rohwer Nadine Rohwer Adelheid Jung Michael Rothe Karsten H. Weylandt Karsten H. Weylandt Ulf Elbelt Ulf Elbelt |
| author_sort | Yanan Xiao |
| collection | DOAJ |
| description | ObjectiveDyslipidemia, in particular elevated triglycerides (TGs) contribute to increased cardiovascular risk in type 2 diabetes mellitus (T2DM). In this pilot study we aimed to assess how increased TGs affect hepatic fat as well as polyunsaturated fatty acid (PUFA) metabolism and oxylipin formation in T2DM patients.Methods40 patients with T2DM were characterized analyzing routine lipid blood parameters, as well as medical history and clinical characteristics. Patients were divided into a hypertriglyceridemia (HTG) group (TG ≥ 1.7mmol/l) and a normal TG group with TGs within the reference range (TG < 1.7mmol/l). Profiles of PUFAs and their oxylipins in plasma were measured by gas chromatography and liquid chromatography/tandem mass spectrometry. Transient elastography (TE) was used to assess hepatic fat content measured as controlled attenuation parameter (CAP) (in dB/m) and the degree of liver fibrosis measured as stiffness (in kPa).ResultsMean value of hepatic fat content measured as CAP as well as body mass index (BMI) were significantly higher in patients with high TGs as compared to those with normal TGs, and correlation analysis showed higher concentrations of TGs with increasing CAP and BMI scores in patients with T2DM. There were profound differences in plasma oxylipin levels between these two groups. Cytochrome P450 (CYP) and lipoxygenase (LOX) metabolites were generally more abundant in the HTG group, especially those derived from arachidonic acid (AA), eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), γ-linolenic acid (γ-LA), and α-linolenic acid (α-LA), and a strong correlation between TG levels and plasma metabolites from different pathways was observed.ConclusionsIn adult patients with T2DM, elevated TGs were associated with increased liver fat and BMI. Furthermore, these patients also had significantly higher plasma levels of CYP- and LOX- oxylipins, which could be a novel indicator of increased inflammatory pathway activity, as well as a novel target to dampen this activity. |
| first_indexed | 2024-03-12T14:25:49Z |
| format | Article |
| id | doaj.art-ed0233e777b64162b81114d4fe8d3620 |
| institution | Directory Open Access Journal |
| issn | 1664-2392 |
| language | English |
| last_indexed | 2024-03-12T14:25:49Z |
| publishDate | 2023-08-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Endocrinology |
| spelling | doaj.art-ed0233e777b64162b81114d4fe8d36202023-08-18T08:20:26ZengFrontiers Media S.A.Frontiers in Endocrinology1664-23922023-08-011410.3389/fendo.2023.11952471195247Bioactive oxylipins in type 2 diabetes mellitus patients with and without hypertriglyceridemiaYanan Xiao0Yanan Xiao1Anne Pietzner2Anne Pietzner3Nadine Rohwer4Nadine Rohwer5Nadine Rohwer6Adelheid Jung7Michael Rothe8Karsten H. Weylandt9Karsten H. Weylandt10Ulf Elbelt11Ulf Elbelt12Division of Medicine, Department of Gastroenterology, Metabolism and Oncology, University Hospital Ruppin-Brandenburg, Brandenburg Medical School, Neuruppin, GermanyMedical Department, Division of Psychosomatic Medicine, Campus Benjamin Franklin, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, GermanyDivision of Medicine, Department of Gastroenterology, Metabolism and Oncology, University Hospital Ruppin-Brandenburg, Brandenburg Medical School, Neuruppin, GermanyFaculty of Health Sciences, Joint Faculty of the Brandenburg University of Technology, Brandenburg Medical School and University of Potsdam, Potsdam, GermanyDivision of Medicine, Department of Gastroenterology, Metabolism and Oncology, University Hospital Ruppin-Brandenburg, Brandenburg Medical School, Neuruppin, GermanyFaculty of Health Sciences, Joint Faculty of the Brandenburg University of Technology, Brandenburg Medical School and University of Potsdam, Potsdam, GermanyDepartment of Molecular Toxicology, German Institute of Human Nutrition Potsdam-Rehbruecke, Nuthetal, GermanyDivision of Medicine, Department of Gastroenterology, Metabolism and Oncology, University Hospital Ruppin-Brandenburg, Brandenburg Medical School, Neuruppin, GermanyLipidomix, Berlin, GermanyDivision of Medicine, Department of Gastroenterology, Metabolism and Oncology, University Hospital Ruppin-Brandenburg, Brandenburg Medical School, Neuruppin, GermanyFaculty of Health Sciences, Joint Faculty of the Brandenburg University of Technology, Brandenburg Medical School and University of Potsdam, Potsdam, GermanyDivision of Medicine, Department of Gastroenterology, Metabolism and Oncology, University Hospital Ruppin-Brandenburg, Brandenburg Medical School, Neuruppin, GermanyMedical Department, Division of Psychosomatic Medicine, Campus Benjamin Franklin, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, GermanyObjectiveDyslipidemia, in particular elevated triglycerides (TGs) contribute to increased cardiovascular risk in type 2 diabetes mellitus (T2DM). In this pilot study we aimed to assess how increased TGs affect hepatic fat as well as polyunsaturated fatty acid (PUFA) metabolism and oxylipin formation in T2DM patients.Methods40 patients with T2DM were characterized analyzing routine lipid blood parameters, as well as medical history and clinical characteristics. Patients were divided into a hypertriglyceridemia (HTG) group (TG ≥ 1.7mmol/l) and a normal TG group with TGs within the reference range (TG < 1.7mmol/l). Profiles of PUFAs and their oxylipins in plasma were measured by gas chromatography and liquid chromatography/tandem mass spectrometry. Transient elastography (TE) was used to assess hepatic fat content measured as controlled attenuation parameter (CAP) (in dB/m) and the degree of liver fibrosis measured as stiffness (in kPa).ResultsMean value of hepatic fat content measured as CAP as well as body mass index (BMI) were significantly higher in patients with high TGs as compared to those with normal TGs, and correlation analysis showed higher concentrations of TGs with increasing CAP and BMI scores in patients with T2DM. There were profound differences in plasma oxylipin levels between these two groups. Cytochrome P450 (CYP) and lipoxygenase (LOX) metabolites were generally more abundant in the HTG group, especially those derived from arachidonic acid (AA), eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), γ-linolenic acid (γ-LA), and α-linolenic acid (α-LA), and a strong correlation between TG levels and plasma metabolites from different pathways was observed.ConclusionsIn adult patients with T2DM, elevated TGs were associated with increased liver fat and BMI. Furthermore, these patients also had significantly higher plasma levels of CYP- and LOX- oxylipins, which could be a novel indicator of increased inflammatory pathway activity, as well as a novel target to dampen this activity.https://www.frontiersin.org/articles/10.3389/fendo.2023.1195247/fulloxylipinstype 2 diabetes mellituspolyunsaturated fatty acidscontrolled attenuation parameterhypertriglyceridemia |
| spellingShingle | Yanan Xiao Yanan Xiao Anne Pietzner Anne Pietzner Nadine Rohwer Nadine Rohwer Nadine Rohwer Adelheid Jung Michael Rothe Karsten H. Weylandt Karsten H. Weylandt Ulf Elbelt Ulf Elbelt Bioactive oxylipins in type 2 diabetes mellitus patients with and without hypertriglyceridemia Frontiers in Endocrinology oxylipins type 2 diabetes mellitus polyunsaturated fatty acids controlled attenuation parameter hypertriglyceridemia |
| title | Bioactive oxylipins in type 2 diabetes mellitus patients with and without hypertriglyceridemia |
| title_full | Bioactive oxylipins in type 2 diabetes mellitus patients with and without hypertriglyceridemia |
| title_fullStr | Bioactive oxylipins in type 2 diabetes mellitus patients with and without hypertriglyceridemia |
| title_full_unstemmed | Bioactive oxylipins in type 2 diabetes mellitus patients with and without hypertriglyceridemia |
| title_short | Bioactive oxylipins in type 2 diabetes mellitus patients with and without hypertriglyceridemia |
| title_sort | bioactive oxylipins in type 2 diabetes mellitus patients with and without hypertriglyceridemia |
| topic | oxylipins type 2 diabetes mellitus polyunsaturated fatty acids controlled attenuation parameter hypertriglyceridemia |
| url | https://www.frontiersin.org/articles/10.3389/fendo.2023.1195247/full |
| work_keys_str_mv | AT yananxiao bioactiveoxylipinsintype2diabetesmellituspatientswithandwithouthypertriglyceridemia AT yananxiao bioactiveoxylipinsintype2diabetesmellituspatientswithandwithouthypertriglyceridemia AT annepietzner bioactiveoxylipinsintype2diabetesmellituspatientswithandwithouthypertriglyceridemia AT annepietzner bioactiveoxylipinsintype2diabetesmellituspatientswithandwithouthypertriglyceridemia AT nadinerohwer bioactiveoxylipinsintype2diabetesmellituspatientswithandwithouthypertriglyceridemia AT nadinerohwer bioactiveoxylipinsintype2diabetesmellituspatientswithandwithouthypertriglyceridemia AT nadinerohwer bioactiveoxylipinsintype2diabetesmellituspatientswithandwithouthypertriglyceridemia AT adelheidjung bioactiveoxylipinsintype2diabetesmellituspatientswithandwithouthypertriglyceridemia AT michaelrothe bioactiveoxylipinsintype2diabetesmellituspatientswithandwithouthypertriglyceridemia AT karstenhweylandt bioactiveoxylipinsintype2diabetesmellituspatientswithandwithouthypertriglyceridemia AT karstenhweylandt bioactiveoxylipinsintype2diabetesmellituspatientswithandwithouthypertriglyceridemia AT ulfelbelt bioactiveoxylipinsintype2diabetesmellituspatientswithandwithouthypertriglyceridemia AT ulfelbelt bioactiveoxylipinsintype2diabetesmellituspatientswithandwithouthypertriglyceridemia |